Physician profile

Beth A Piper

Endocrinology, Diabetes & Metabolism · Syracuse, NY

NPI 1740731876

$1,784.35

in general payments reported to CMS, 2019-2025

18 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $371.96 2019-2020
Novo Nordisk INC $294.36 2019-2021
Sanofi-Aventis U.S. LLC $222.36 2019-2020
Astrazeneca Pharmaceuticals LP $146.97 2019-2020
Lilly USA, LLC $144.06 2019-2020
Radius Health, INC. $140.10 2019
Insulet Corporation $107.80 2019
Mannkind Corporation $63.69 2019-2020
Abbvie INC. $61.59 2019-2022
Medtronic Minimed, INC. $48.76 2020
Ibsa Pharma INC. $46.30 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $36.97 2019-2020
Eisai INC. $24.94 2019
Lifescan, INC. $17.36 2020
Pfizer INC. $16.48 2019
Show all 18 companies
CompanyGeneral paymentsYearsTop products
Merck Sharp & Dohme LLC $14.72 2020
Amarin Pharma, INC. $13.42 2019
Grifols USA, LLC $12.51 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Beth A Piper

$1,784.35

in general payments reported 2019-2025

Years
2019-2022
Top company
Amgen INC.

https://glasscript.com/doctor/2777079/beth-a-piper

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.